NF-κB is the oncogenic driver whose indirect inhibition dominated therapeutic attempts, as direct targeting is known to cause adverse effects due to housekeeping and tumor suppressive roles of NF-κB [158]. The gene discussed is NFKB1; the disease is neoplasm.